NADAC acquisition cost data for SAPHRIS 2.5 MG TAB SUBLINGUAL. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00456240206 | $19.23 | 2022-03-23 | Rx |
| 00456240260 | $19.23 | 2022-03-23 | Rx |
| 00456240206 | $19.23 | 2022-03-23 | Rx |
| 00456240260 | $19.23 | 2022-03-23 | Rx |
| 00456240206 | $19.23 | 2022-03-23 | Rx |
| 00456240260 | $19.23 | 2022-03-23 | Rx |
| 00456240206 | $19.23 | 2022-03-23 | Rx |
| 00456240260 | $19.23 | 2022-03-23 | Rx |
| 00456240206 | $19.23 | 2022-03-23 | Rx |
| 00456240260 | $19.23 | 2022-03-23 | Rx |
Generic: Asenapine Maleate | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $115.4M | 118,424 | 16,336 | $20.55 |
| 2020 | $107.7M | 107,877 | 14,400 | $20.61 |
| 2021 | $39.9M | 41,071 | 8,056 | $20.00 |
| 2022 | $12.3M | 11,704 | 2,513 | $20.15 |
| 2023 | $9.0M | 7,740 | 1,135 | $20.70 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $838.6K | 687 | 123 |
| Texas | $571.0K | 435 | 71 |
| New York | $507.9K | 489 | 66 |
| Michigan | $429.3K | 398 | 57 |
| Florida | $408.9K | 304 | 47 |
| Ohio | $336.7K | 324 | 49 |
| Indiana | $312.1K | 308 | 43 |
| Oregon | $303.0K | 240 | 36 |
| Wisconsin | $297.5K | 276 | 32 |
| Tennessee | $293.1K | 249 | 39 |
| Virginia | $289.7K | 182 | 30 |
| North Carolina | $272.4K | 209 | 39 |
| Colorado | $254.0K | 237 | 32 |
| Washington | $229.6K | 188 | 25 |
| Illinois | $228.0K | 234 | 33 |
| Kentucky | $225.7K | 188 | 29 |
| Minnesota | $213.5K | 182 | 21 |
| Missouri | $207.7K | 161 | 29 |
| Kansas | $197.8K | 142 | 19 |
| Maryland | $189.5K | 104 | 19 |
| Pennsylvania | $187.0K | 174 | 24 |
| New Jersey | $181.4K | 178 | 24 |
| Iowa | $176.2K | 159 | 20 |
| Georgia | $148.1K | 148 | 23 |
| Arizona | $145.6K | 104 | 21 |
| Connecticut | $145.4K | 90 | 20 |
| Massachusetts | $145.1K | 141 | 18 |
| Louisiana | $112.8K | 114 | 22 |
| South Carolina | $111.0K | 115 | 14 |
| Nebraska | $107.7K | 80 | 12 |
| Alabama | $98.9K | 83 | 16 |
| Puerto Rico | $87.0K | 127 | 14 |
| Maine | $83.8K | 80 | N/A |
| Utah | $78.7K | 78 | N/A |
| Mississippi | $71.3K | 59 | 17 |
| Oklahoma | $68.8K | 54 | N/A |
| New Hampshire | $64.8K | 56 | N/A |
| West Virginia | $59.9K | 53 | N/A |
| South Dakota | $46.8K | 39 | N/A |
| Nevada | $43.3K | 31 | N/A |
| Montana | $43.0K | 53 | N/A |
| Rhode Island | $35.7K | 34 | N/A |
| Arkansas | $35.5K | 43 | N/A |
| District of Columbia | $31.7K | 25 | N/A |
| Idaho | $29.4K | 35 | N/A |
| Alaska | $17.9K | 13 | N/A |
| New Mexico | $16.2K | 11 | N/A |
| Vermont | $7.7K | 12 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.